New drug SIM0278 takes first step in human safety trial
NCT ID NCT06022354
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested the safety and tolerability of a new drug called SIM0278 in 60 healthy Chinese adults. Participants received either a single or multiple doses of the drug or a placebo via injection. The main goal was to check for side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SIM0278
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Qingdao University
Qingdao, China, Shandong, 266001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults